Reviva Pharmaceuticals Holdings, Inc. (RVPH): Cash & Equivalents
$14.44M
As of 2025-12-31
$19.89M
As of 2026-06-30
-8.0%
3-year compound annual growth
+10.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.44M | +7.1% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $13.48M | -42.3% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $23.37M | +26.2% | 2025-04-03, Balance as of period end |
| 2022-12-31 | $18.52M | -37.6% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $29.69M | +238.9% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $8.76M | n/a | 2022-03-15, Balance as of period end |
| 2020-02-29 | $69.3K | n/a | 2020-05-04, Balance as of period end |
| 2019-12-31 | $193 | n/a | 2021-05-07, Balance as of period end |
| 2019-02-28 | $313.0K | n/a | 2020-05-04, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $14.44M | +7.1% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $14.60M | -36.1% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $1.24M | -2.1% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $14.67M | -22.2% |
| Aditxt, Inc. (ADTX) | 2024-12-31 | $833.0K | +757.9% |
| Cingulate Inc. (CING) | 2025-12-31 | $10.95M | -10.3% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $13.20M | -43.3% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $7.71M | -74.5% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $5.21M | -16.1% |
Compare RVPH, APRE, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗